Get the Stockscreener App
0.054
7.57%
0.0038
Geovax Labs Inc stock is traded at $0.054, with a volume of 504.
It is up +7.57% in the last 24 hours and down -6.25% over the past month.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
See More
Previous Close:
$0.0502
Open:
$0.054
24h Volume:
504
Relative Volume:
0.04
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-25.52%
1M Performance:
-6.25%
6M Performance:
-51.35%
1Y Performance:
+102.93%
1-Day Range:
$0.054
$0.054
1-Week Range:
$0.0502
$0.072
52-Week Range:
$0.0266
$34.93
Geovax Labs Inc Stock (GOVXW) Company Profile
Name
Geovax Labs Inc
Sector
Industry
Phone
678 384 7220
Address
1900 Lake Park Drive, Suite 380, Smyrna
Compare GOVXW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOVXW
Geovax Labs Inc
|
0.054 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Geovax Labs Inc Stock (GOVXW) Latest News
Short Interest in GeoVax Labs, Inc. (NASDAQ:GOVX) Drops By 12.3% - Defense World
GeoVax Labs CEO Makes Bold Stock Purchase! - TipRanks
Geovax labs CEO David Dodd acquires $10,800 in common stock - Investing.com India
Geovax Labs stock hits 52-week low at $1.09 amid market challenges - Investing.com
Roth Capital Forecasts GeoVax Labs FY2029 Earnings - Defense World
GeoVax Labs (NASDAQ:GOVX) Earns Buy Rating from D. Boral Capital - Defense World
GeoVax Labs Advances Vaccine Trials and Expands Operations - TipRanks
GeoVax Labs Earnings Call: Mixed Sentiments and Strategic Plans - TipRanks
GeoVax Reports 2024 Year-End Financial Results and Provides Business Update - TradingView
Geovax Labs Inc (GOVX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Geovax Labs Inc (GOVX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com
Earnings call transcript: GeoVax Q4 2024 highlights ongoing challenges By Investing.com - Investing.com South Africa
GEOVAX LABS Earnings Results: $GOVX Reports Quarterly Earnings - Nasdaq
GeoVax Labs Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: GeoVax Q4 2024 highlights ongoing challenges - Investing.com
What's Next: Geovax Labs's Earnings Preview - Benzinga
GEOVAX LABS Earnings Preview: Recent $GOVX Insider Trading, Hedge Fund Activity, and More - Nasdaq
GeoVax Labs IncEnters Placement Agency And Securities Purchase Agreements With A.G.P./Alliance Global PartnersSEC Filing - MarketScreener
GeoVax Labs Inc expected to post a loss of 77 cents a shareEarnings Preview - TradingView
GeoVax Prepares to Announce Fourth Quarter and Full Year 2024 Financial Results - citybuzz -
GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025 - Yahoo Finance
GeoVax Labs, Inc. (NASDAQ:GOVX) Given Average Recommendation of “Buy” by Analysts - Defense World
International - Financial Content
GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UK - Yahoo Finance
GeoVax CEO to Present at 37th Annual Roth Conference, Highlighting COVID-19 Vaccine and Cancer Therapy Research - citybuzz -
GeoVax to Present at the 37th Annual Roth Conference - Yahoo Finance
GeoVax Labs, Inc. (NASDAQ:GOVX) Short Interest Up 35.5% in February - Defense World
News - Financial Content
Geovax Labs Inc (NASDAQ: GOVX) Could Fell Another -164.9% - Stocks Register
GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy - Yahoo Finance
GeoVax Labs’ (GOVX) “Buy” Rating Reiterated at D. Boral Capital - Defense World
GeoVax Response to WHO's Third Declaration of Mpox as a Public Health Emergency of International Concern - Yahoo Finance
GeoVax Labs (GOVX) Projected to Post Earnings on Thursday - Defense World
GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness - Yahoo Finance
Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification - Yahoo Finance
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Rating of “Buy” from Analysts - Defense World
GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health - Yahoo Finance
GeoVax shareholders approve warrant exercises - MSN
GeoVax to Highlight Mpox Vaccine Development at Emerging Growth Conference - citybuzz -
GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award - Yahoo Finance
Was Geovax Labs Inc (GOVX)’s session last reading good? - US Post News
GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs - Financial Content
Stock Surge: Geovax Labs Inc (GOVX) Closes at 1.77, Marking a -7.33 Increase/Decrease - The Dwinnex
Analysts review Geovax Labs Inc’s rating - Knox Daily
GeoVax to Present Strategic Vision for Cancer and Infectious Disease Treatments at Major Biotech Conference - citybuzz -
GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference - Yahoo Finance
Trump's Stargate Initiative: A New Era For Healthcare Innovation - Evrim Ağacı
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative - Yahoo Finance
GeoVax Labs (NASDAQ:GOVXW) Shares Down 11.3% – Here’s Why - Defense World
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability - Yahoo Finance
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide - Yahoo Finance
Geovax Labs Inc Stock (GOVXW) Financials Data
There is no financial data for Geovax Labs Inc (GOVXW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.89%
0.13%
Cap:
|
Volume (24h):